Name: Guido Grentzmann
Role: Founder / CSO
Guido Grentzmann founded Opterion in 2012 with the aim to develop a new solution for peritoneal dialysis that will reduce side effects. More than 25 years ago and after he spent some time in academic research in bacterial and viral translational regulation, Guido went into pharmaceutical R&D, working on therapeutical targets, biomarkers and signal pathways in different therapeutic areas, in different roles.
The main driver for the foundation of Opterion was to develop new concepts to minimize the side-effects of dialysis, a lifelong chronic treatment. After 10 years, the Opterion team has grown and moved to Muttenz, near Basel in 2021.
To be closer to the new Opterion headquarters, Guido has relocated to Basel and is discovering the city on the Rhine. Besides working for Opterion, Guido likes spending time with friends and folks, and enjoys music. Once a year, Guido goes for a week hiking in the mountains.